{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:46:25Z","timestamp":1782157585058,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T00:00:00Z","timestamp":1092873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>The gefitinib compassionate-use programme has enabled &gt;39,000 patients worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of gefitinib treatment in Chinese patients who enrolled into the 'Iressa' Expanded Access Programme (EAP) at the Peking Union Medical College Hospital.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Thirty-one patients with advanced or metastatic non-small-cell lung cancer (NSCLC) that had progressed after prior systemic chemotherapy were eligible to receive oral gefitinib 250 mg\/day as part of the EAP. Treatment was continued until disease progression or unacceptable toxicity occurred. The impact of treatment on disease-related symptoms and quality of life (QoL) was evaluated with the Chinese versions of European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-LC13).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Gefitinib was well tolerated. Adverse events (AEs) were generally mild (grade1 and 2) and reversible. The most frequent AEs were acneform rash and diarrhoea. Only one patient withdrew from the study due to a drug-related AE. The objective tumour response rate was 35.5% (95% confidence interval [CI]: 18.6\u201352.3); median progression-free survival was 5.5 months (95% CI, 1.6 to 9.4); median overall survival was 11.5 months (95% CI, 5.6 to 17.3). The QoL response rates for five functioning scales and global QoL varied from 56\u201388%. The main symptom response rates varied from 44\u201384%. QoL and symptom response were correlated with objective tumour response.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Gefitinib demonstrated safety and efficacy as monotherapy in this series of Chinese patients with advanced NSCLC and was also associated with remarkable symptom relief and improvement in QoL. Although clinical trials are needed to confirm these positive findings, the data suggest that treatment with gefitinib may be beneficial for some Chinese patients who do not respond to chemotherapy and have poor prognosis.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-2407-4-51","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T06:23:13Z","timestamp":1093414993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme"],"prefix":"10.1186","volume":"4","author":[{"given":"Xin-Lin","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,8,19]]},"reference":[{"key":"141_CR1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","volume":"311","author":"Non-small Cell Lung Cancer Collaborative Group","year":"1995","unstructured":"Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trails. BMJ. 1995, 311: 899-909.","journal-title":"BMJ"},{"key":"141_CR2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/107327480100800404","volume":"8","author":"EB Haura","year":"2001","unstructured":"Haura EB: Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control. 2001, 8: 326-336.","journal-title":"Cancer Control"},{"issue":"Suppl 1","key":"141_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-200060001-00001","volume":"60","author":"EK Rowinsky","year":"2000","unstructured":"Rowinsky EK: The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs. 2000, 60 (Suppl 1): 1-14.","journal-title":"Drugs"},{"key":"141_CR4","first-page":"515","volume":"3","author":"V Rusch","year":"1997","unstructured":"Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997, 3: 515-522.","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"141_CR5","first-page":"2379","volume":"53","author":"V Rusch","year":"1993","unstructured":"Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993, 53 (Suppl): 2379-2385.","journal-title":"Cancer Res"},{"key":"141_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/bjc.1986.172","volume":"54","author":"T Cerny","year":"1986","unstructured":"Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N: Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986, 54: 265-269.","journal-title":"Br J Cancer"},{"key":"141_CR7","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/annonc\/mdg250","volume":"14","author":"K Nakagawa","year":"2003","unstructured":"Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003, 14: 922-930. 10.1093\/annonc\/mdg250.","journal-title":"Ann Oncol"},{"key":"141_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet. 2003, 361: 137-139. 10.1016\/S0140-6736(03)12190-3.","journal-title":"Lancet"},{"key":"141_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa\u00ae) tablets. Oncologist. 2003, 8: 303-306. 10.1634\/theoncologist.8-4-303.","journal-title":"Oncologist"},{"key":"141_CR10","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003, 21: 2237-2246. 10.1200\/JCO.2003.10.038.","journal-title":"J Clin Oncol"},{"key":"141_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"141_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85: 365-376. 10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"141_CR13","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group: The EORTC QLQ-C30 Scoring Manual. 2001, European Organization for Research and Treatment of Cancer, Brussels, Belgium, 3","edition":"3"},{"key":"141_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.bjc.6690085","volume":"79","author":"RJ Stephens","year":"1999","unstructured":"Stephens RJ, Hopwood P, Girling DJ: Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 1999, 79: 538-544. 10.1038\/sj.bjc.6690085.","journal-title":"Br J Cancer"},{"key":"141_CR15","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2001.19.8.2123","volume":"19","author":"JA Langendijk","year":"2001","unstructured":"Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Lamers RJ, Slotman BJ, Wouters EF: Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2001, 19: 2123-2133.","journal-title":"J Clin Oncol"},{"key":"141_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0169-5002(01)00188-X","volume":"33","author":"JW van Putten","year":"2001","unstructured":"van Putten JW, Baas P, Codrington H, Kwa HB, Muller M, Aaronson N, Groen HJ: Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2001, 33: 289-298. 10.1016\/S0169-5002(01)00188-X.","journal-title":"Lung Cancer"},{"key":"141_CR17","doi-asserted-by":"crossref","unstructured":"Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290 (16): 2149-2158. 2003 Oct 22","DOI":"10.1001\/jama.290.16.2149"},{"key":"141_CR18","unstructured":"Forsythe B, Faulkner K: Safety and tolerability of gefitinib ('Iressa', ZD1839) in advanced NSCLC: overview of clinical experience. Poster presented at ERS 13th Annual Congress, Vienna, Austria, Poster no. P327. September 27-October 1, 2003"},{"issue":"Suppl 1","key":"141_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/sonc.2003.50030","volume":"30","author":"RS Herbst","year":"2003","unstructured":"Herbst RS: Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003, 30 (Suppl 1): 30-38. 10.1053\/sonc.2003.50030.","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"141_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/sonc.2003.50031","volume":"30","author":"D Cella","year":"2003","unstructured":"Cella D: Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol. 2003, 30 (Suppl 1): 39-48. 10.1053\/sonc.2003.50031.","journal-title":"Semin Oncol"},{"key":"141_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1378\/chest.113.2.467","volume":"113","author":"A Montazeri","year":"1998","unstructured":"Montazeri A, Gillis CR, McEwen J: Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest. 1998, 113: 467-481.","journal-title":"Chest"},{"key":"141_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1023\/A:1008981520920","volume":"9","author":"H Zhao","year":"2000","unstructured":"Zhao H, Kanda K: Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res. 2000, 9: 129-137. 10.1023\/A:1008981520920.","journal-title":"Qual Life Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-4-51\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:35:23Z","timestamp":1728304523000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-4-51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-4-51","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,19]]},"assertion":[{"value":"22 May 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"51"}}